Viral protein Nef enables a step toward off-the-shelf CAR T cell therapy for cancer
CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a ...
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for ...
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma ...
In a first, Safdarjung Hospital uses CAR T-cell therapy to treat cancer patient
CAR T-cell therapy is an advanced immunotherapy that harnesses the power of a patient’s own immune cells, specifically ...
Mena FN3 天
Engineering Immunity: The Breakthroughs Driving The CAR T-Cell Therapy Market (Growing At A ...
The CAR T-cell therapy market size was valued at $2.6 billion in 2022 and is estimated to reach $35.9 billion by 2032, exhibiting a CAGR of 28.5% by 2032. PORTLAND, OR, UNITED STATES, January 28 ...
Natural killer cells, a rising alternative to CAR-T cell therapy
Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...
Indore: SSH Performs State’s First CAR T-Cell Therapy On Blood Cancer Patient
The Super Specialty Hospital (SSH) administration here has claimed to have achieved a medical milestone by performing CAR ...
Targeted Oncology4 天
Novel CAR T-Cell Therapy GCC19CART Active in Refractory mCRC
Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical ...
Pharmaceutical Technology5 小时
How AI is streamlining cell and gene therapy manufacturing
AI could deliver substantially greater efficiencies in cell and gene therapy manufacturing and enable more patients to ...
News Medical2 天
A deep dive in CAR+ T-cell therapy
In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...
FierceBiotech1 天
Cargo offloads CAR-T along with half of its workforce in wake of low efficacy, toxic side ...
The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...
Peninsula biotech moves from IPO to chopping half its workforce in little more than a year
After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...